Immune escape mediated by the EGFR-derived signal: From Mechanism to Therapy

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09237
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Iwate Medical University (2017); Miyagi Prefectural Hospital Organization Miyagi Cancer Center (2015-2016)
• Principal Investigator: Mamondo Makoto 岩手医科大学, 医学部, 教授 (40344676)
• Co-Investigator(Kenkyū-buntansha): 田中 伸幸 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん先進治療開発研究部, 部長 (60280872)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 非小細胞肺癌 / EGFR

Outline of Final Research Achievements

Immune checkpoint inhibitors targeting PD-L1 and PD-1 often show synergistic effects on NSCLCs. To elucidate the role of EGFR-mediated signal on lung tumor immunology, LLC cells were examined for the immune modulator expression. Although LAG-3 and B7-H3 expression was negative, a fair amount of PD-L1 was detected. We then established PD-L1 knockout cells and implanted into syngeneic mice, but TIL infiltration was relatively low. To increase TIL infiltration we introduced CTIIA, and succeeded in MHC up-regulation.

Free Research Field

呼吸器腫瘍学